Pilot Study on Neoadjuvant Dapagliflozin in High-Risk Prostate Cancer
A pilot study is assessing the safety and tolerability of dapagliflozin in patients with high-risk prostate cancer prior to surgery.
Phase III
prostate cancer treatment
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Portfolio teams should consider the potential for dapagliflozin to expand its indications beyond diabetes into oncology.
Why it matters
The pilot study on dapagliflozin as a neoadjuvant therapy in high-risk prostate cancer could redefine treatment protocols in oncology. Successful outcomes may lead to expanded indications for dapagliflozin, enhancing its market presence beyond diabetes.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results on tolerability, safety, and efficacy in tumor shrinkage from this pilot study.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.